 A 2:1 randomisation is chosen favouring the experimental arm since a large body of data is available on gemcitabine alone and since sufficient efficacy and toxicity data shall be gained in the experimental arm. In addition, the patients motivation to take part in the trial will be greatly enhanced by a greater chance to receive the experimental agent. 